Home Metabolism DPP

DPP

Other Metabolism Related Inhibitors

Dehydrogenase Transferase Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR Carbonic Anhydrase

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S5079 Sitagliptin Sitagliptin (MK-0431) is an oral and highly selective DPP-4 inhibitor with an IC50 of 18 nM. It is used for the treatment of type 2 diabetes.
Small Sci, 2025, 5(12):e202500140
Pharmacol Res, 2025, 215:107696
Sci Rep, 2025, 15(1):30226
S3033 Vildagliptin Vildagliptin inhibits DPP−4 with IC50 of 2.3 nM.
Int J Mol Sci, 2024, 25(18)9760
J Clin Invest, 2023, 133(12)e165933
Oncoimmunology, 2023, 12(1):2268257
S4002 Sitagliptin phosphate monohydrate Sitagliptin phosphate monohydrate (MK-0431) is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts.
Small Sci, 2025, 5(12):e202500140
J Cell Mol Med, 2025, 29(11):e70581
Front Oncol, 2021, 11:704024
Verified customer review of Sitagliptin phosphate monohydrate
S8455 Talabostat (Val-boroPro, PT-100) Mesylate Talabostat (Val-boroPro, PT-100) is a dipeptidyl peptidase inhibitor with IC50 values of <4 nM, 4 nM, 11 nM, 310 nM, 560 nM and 390 nM for DPP-IV, DPP8, DPP9, QPP, FAP and PEP respectively. It has antineoplastic and hematopoiesis- stimulating activities.
Int J Mol Sci, 2025, 26(5)2237
J Oral Microbiol, 2024, 16(1):2373040
Brain Res, 2024, S0006-8993(24)00383-4
S9631 Puromycin aminonucleoside Puromycin aminonucleoside (NSC 3056, PAN, Stylomycin aminonucleoside, ARDMA, SAN), the aminonucleoside portion of the antibiotic puromycin, is a reversible inhibitor of dipeptidyl-peptidase II and cytosol alanyl aminopeptidase that induces apoptosis in mesangial cells (MCs) accompanied by declined cell viability and enhanced inflammatory response.This compound can be used to induce animal models of Kidney Disease.
PLoS Pathog, 2025, 21(9):e1013549
bioRxiv, 2025, 2025.08.15.670603
mBio, 2024, 15(12):e0194524
S1540 Saxagliptin (BMS-477118) Saxagliptin (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with an IC50 of 26 nM.
Turk J Pharm Sci, 2019, 16(2):227-233
Cancer Cell, 2018, 34(4):659-673
J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1083:249-257
Verified customer review of Saxagliptin (BMS-477118)
S8565 MK-3102 (Omarigliptin) Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5).
NYMC Student Theses and Dissertations, 2023,
Acta Pharmacol Sin, 2021, 1-9
Front Behav Neurosci, 2021, 15:705579
S2868 Alogliptin (SYR-322) benzoate Alogliptin (SYR-322) benzoate is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
Cell Rep, 2017, 20(7):1692-1704
S5365 Alogliptin Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4) with IC50 values of 2.63 nM and exhibits greater than 10,000 fold selectivity over the closely related serine proteases DPP-8 and DPP-9.
Sci Adv, 2021, 7(27)eabh3032
E1188 Brensocatib Brensocatib (AZD7986, INS1007) is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1). It reduces the activity of all major neutrophil serine proteases (NSPs) including, neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in patients with bronchiectasis.
Nat Commun, 2024, 15(1):6519

Signaling Pathway Map